India Immuno-Oncology Drugs Market
- 2026 年市場規模
- USD 6.2 Bn
- 2033 年預估規模
- USD 14.37 Bn
- 年複合成長率 CAGR
- 12.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
India Immuno-Oncology Drugs Market, By Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab, Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine), Cancer Vaccines (Gardasil, Cervarix)), By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, Others), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies)
報告摘要
Immuno-Oncology also known as cancer immunotherapy, is a form of cancer treatment that utilizes immune system of the body to manage, prevent, and destroy cancer. Immuno-oncologists are growing and becoming a part of cancer care group by rapidly increasing the cancer care area. The researchers did study on how to attack cancer by the immune system. Some of them work in labs on creating new treatments and some of them interact between the immune system and cancer cells.
India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to increase to US$ 550 Mn by 2028, exhibiting a CAGR of 13.1% over the forecast period.
Market Dynamics
The rising incidence of cancer, introduction of novel immuno-oncology therapies with lesser side effects, increasing government engagement to increase cancer diagnosis, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Indian immuno-oncology drugs market over the forecast period.
According to the National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many people die every day due to tobacco-related cancer diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women, in 2018.
Moreover, The WHO also suggested that people with low and middle income countries should have necessary data for cancer policies because of lack of awareness for treatment availability.
Key features of the study
• This report provides an in-depth analysis of the India immuno-oncology drugs market provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The India immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India immuno-oncology drugs market
Market Segmentation
• By Drug Type (Revenue, USD Bn, 2021-2033)
o Immune Checkpoint Inhibitors
Nivolumab
Atezolimumab
Pembrolizuma
Durvalumab
o Monoclonal Antibodies
Rituximab
Trastazumab
Bevacizumab
Nimotuzumab
Pertuzumab
Ado-Trastuzumab Emtansine
o Cancer Vaccines
Gardasil
Cervarix
• By Cancer Type (Revenue, USD Bn, 2021-2033)
o Lung Cancer
o Blood Cancer
o Breast Cancer
o Ovarian Cancer
o Cervical Cancer
o Colorectal Cancer
o Stomach Cancer
o Head & Neck Cancer
o Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Online Pharmacies
o Retail Pharmacies
o Hospital Pharmacies
• Key Players
o Amgen Inc.
o Hoffmann-La Roche AG.
o Intas Pharmaceuticals Ltd.
o AstraZeneca plc
o Mylan N.V.
o Reddy's Laboratories
o Bristol - Myers Squibb
o Merck & Co., Inc.
o BIOCAD-Biotechnology company
o Reliance Life Sciences
o Biocon Limited
o Hetero Drugs Limited
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Cancer Type
Market Snapshot, By Distribution Channel
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. India Immuno-Oncology Drugs Market, By Drug Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Immune Checkpoint Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
Segment Trends
o Nivolumab
o Atezolimumab
o Pembrolizuma
o Durvalumab
o Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
Segment Trends
o Rituximab
o Trastazumab
o Bevacizumab
o Nimotuzumab
o Pertuzumab
o Ado-Trastuzumab Emtansine
o Cancer Vaccines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
Segment Trends
o Gardasil
o Cervarix
5. India Immuno-Oncology Drugs Market, By Cancer Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Blood Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Ovarian Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Cervical Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Colorectal Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Stomach Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Head & Neck Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. India Immuno-Oncology Drugs Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Amgen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
F. Hoffmann-La Roche AG.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Intas Pharmaceuticals Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AstraZeneca plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mylan N.V.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Dr. Reddy's Laboratories
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bristol - Myers Squibb
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Merck & Co., Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BIOCAD-Biotechnology company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Reliance Life Sciences
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Biocon Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Hetero Drugs Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們